An interventional study of Folic Acid 1 MG and Vitamin B6 25 MG in Parkinson&Amp;#39;s Disease, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment
This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
This study's planned enrollment of 150 is above the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Oregon Health and Science University is the lead sponsor of 676 studies on the registry; 136 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 36 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
Daily doses of 1mg folic acid, 25mg vitamin B6, and 1,000 ug vitamin B12.
Dietary Supplement: Folic Acid 1 MG · Dietary Supplement: Vitamin B6 25 MG · Dietary Supplement: Vitamin B12
No vitamin intervention.
Folic Acid 1mg per day
Vitamin B6, 25mg per day
Vitamin B12, 1,000 ug per day
Hyperhomocysteinemia and B vitamin deficiency
Plasma vitamin B12 in subjects with vs without hyperhomocysteinemia
Time frame: baseline measurement
Hyperhomocysteinemia and B vitamin deficiency
Plasma folic acid in subjects with vs without hyperhomocysteinemia
Time frame: baseline measurement
Hyperhomocysteinemia and B vitamin deficiency
Plasma pyridoxine in subjects with vs without hyperhomocysteinemia
Time frame: baseline measurement
Hyperhomocysteinemia and cognitive assessments
Change in total Braincheck score in subjects with vs without hyperhomocysteinemia
Time frame: From enrollment to the end of treatment at 3 months
Hyperhomocysteinemia and measurement of neurofilament light in plasma
Change in plasma neurofilament level in subjects with vs without hyperhomocysteinemia
Time frame: From enrollment to the end of treatment at 3 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University